NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
Clinical Trials
13 trialsNCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT00126594 2016-09-16
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02627144 2016-08-29
Bevacizumab in Metastatic Renal Cancer
Hoffmann-La Roche
Completed
NCT00738530 2016-06-23
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Hoffmann-La Roche
Phase 3 Completed
NCT00796757 2015-05-27
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Hoffmann-La Roche
Phase 2 Completed
NCT00520403 2014-10-13
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00059813 2013-08-26
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00619268 2013-02-15
TORAVA
Centre Leon Berard
Phase 2 Completed
NCT00416429 2012-09-26
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Phase 3 Completed
NCT00083889 2010-01-26
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Pfizer
Phase 3 Completed